In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Eliem Therapeutics (ELYM – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $2.83.
According to TipRanks, Tsao is a 4-star analyst with an average return of 3.0% and a 41.40% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Daré Bioscience, Cabaletta Bio, and Revance Therapeutics.
Currently, the analyst consensus on Eliem Therapeutics is a Moderate Buy with an average price target of $6.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $19.60 and a one-year low of $2.52. Currently, Eliem Therapeutics has an average volume of 19.69K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Read More on ELYM:
